Sotera Health Company
Sotera Health Company provides sterilization, and lab testing and advisory services in the United States, Canada, Europe, and internationally. The company's sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Lab…
Medical - Diagnostics & Research
US, Broadview Heights [HQ]
Ratios
6 Sheets · Starting from 2023Margins, Growth Rates In %
| Ratio | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Profitability | |||||||
| Gross Margin | 47.88 | 50.81 | 54.22 | 55.68 | 55.50 | 48.92 | |
| Profit Margin | -0.79 | -2.62 | -4.58 | 12.55 | -23.27 | 4.90 | |
| Operating Margin | 10.84 | 23.59 | 25.18 | 27.56 | 24.74 | 33.97 | |
|
EPS Growth
|
- - | -201.68 | -81.06 | 415.39 | -302.44 | 121.69 | |
| EPS USD | -2.38 | -7.18 | -13.00 | 41.00 | -83.00 | 18.00 | |
| Return on Assets (ROA) | -0.22 | -0.79 | -1.36 | 4.19 | -7.49 | 1.64 | |
| Return on Equity (ROE) | -13.23 | 3.18 | -8.25 | 19.94 | -66.69 | 11.58 | |
| Return on Invested Capital (ROIC) | -0.86 | 185.59 | 8.68 | 7.31 | 10.36 | 6.43 | |
| Solvency | |||||||
| Equity Ratio | - - | - - | - - | - - | - - | - - | |
| Debt/Assets | 82.62 | 110.37 | 66.47 | 62.88 | 62.66 | 71.66 | |
| Debt/Equity | 5,044.73 | -443.28 | 403.75 | 299.27 | 557.77 | 505.52 | |
| Debt/EBITDA | 676.42 | 811.27 | 627.54 | 487.50 | 490.11 | 391.90 | |
|
Debt/Capitalization
|
98.06 | 129.13 | 80.15 | 74.95 | 84.80 | 83.49 | |
| Long-Term Debt/Capitalization | 98.04 | 129.37 | 80.06 | 74.84 | 83.30 | 83.36 | |
| Interest Debt per Share USD | 9.67 | 10.57 | 7.24 | 6.55 | 7.26 | 8.57 | |
| Debt Growth | - - | 27.29 | -35.94 | -4.45 | 12.04 | 19.12 | |
| Liquidity | |||||||
| Current Ratio | 218.21 | 203.53 | 224.05 | 214.67 | 81.49 | 241.59 | |
| Quick Ratio | 165.92 | 144.77 | 138.60 | 133.86 | 65.12 | 207.19 | |
| Cash Ratio | 67.15 | 50.70 | 72.87 | 66.35 | 50.06 | 130.78 | |
| Operating Cash Flow Ratio | - - | 100 | - - | 100 | - - | - - | |
| Turnover | |||||||
| Inventory Turnover | 1,034.33 | 1,023.90 | 1,098.72 | 760.40 | 1,202.54 | 1,030.93 | |
| Receivables Turnover | 526.90 | 697.54 | 891.87 | 861.02 | 847.12 | 597.82 | |
| Payables Turnover | 838.95 | 911.57 | 714.86 | 566.51 | 602.49 | 754.42 | |
|
Asset Turnover
|
27.55 | 30.16 | 29.63 | 33.39 | 32.19 | 33.52 | |
| Fixed Turnover | 127.23 | 133.74 | 124.76 | 134.85 | 125.30 | 108.07 | |
| Coverage | |||||||
| Interest Coverage | 56.41 | 116.40 | 95.71 | 346.04 | 309.88 | 214.70 | |
| Asset Coverage | - - | - - | 100 | 100 | 100 | 100 | |
| Cash Flow Coverage (CFGR) | 5.34 | 5.23 | 6.57 | 16.05 | 14.23 | -7.73 | |
| EBITDA Coverage | 200 | 200 | 100 | 400 | 300 | 300 | |
| Dividend Coverage | - - | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | 100 | 100 | 100 | 100 | 100 | 300 | |
| Market Prospects | |||||||
| Dividend Yield | 2.85 | 9.68 | - - | - - | - - | - - | |
| Earnings Yield | -0.10 | -0.29 | -0.48 | 1.78 | -10.01 | 1.09 | |
|
Price/Earnings (P/E)
|
-105,254.09 | -34,952.20 | -20,731.18 | 5,626.03 | -998.93 | 9,216.34 | |
| Price/Earnings Growth (PEG) | - - | -173.30 | -255.76 | -13.54 | 3.30 | -75.74 | |
|
Price/Book (P/B)
|
13,928.21 | -1,111.00 | 1,709.80 | 1,121.97 | 666.18 | 1,067.08 | |
| Price/Tangible Book (P/TB) | 13,928.21 | -1,111.00 | 1,709.80 | 1,121.97 | 666.18 | 1,067.08 | |
| Price/Sales (P/S) | 828.04 | 917.22 | 949.98 | 705.96 | 232.46 | 451.26 | |
|
Price/Cash Flow (P/CF)
|
5,167.50 | 4,789.95 | 6,445.52 | 2,335.62 | 839.40 | -2,731.03 | |
| Price/Free CF (P/FCF) | 13,159.56 | 7,778.03 | 11,587.00 | 3,665.80 | 2,441.02 | -1,219.25 | |
| Price/Operating CF (P/OCF) | 5,167.50 | 4,789.95 | 6,445.52 | 2,335.62 | 839.40 | -2,731.03 |